Investigation of Anticholinergic Drugs and Dementia Risk

Understanding Dementia

Dementia is a brain disorder resulting from neurodegenerative processes, leading to cognitive decline and the progressive inability to perform daily activities. Currently, there are no treatments available to modify the disease activity of dementia. Therefore, recognizing and mitigating risk factors that may impact brain health is crucial for prevention.

Short-term Cognitive Impairment from Anticholinergic Drugs

Anticholinergic drugs, commonly prescribed for conditions such as depression, Parkinson’s disease, urinary incontinence, gastrointestinal disorders, and allergies, have been linked to short-term cognitive impairment. Although some reports suggest these drugs may contribute to future cognitive decline, the extent of their impact remains unclear.

Research Study Overview

A study published in The BMJ by researchers from the United Kingdom aimed to explore the long-term associations between anticholinergic drugs and the incidence of dementia. The researchers conducted a nested case-control study utilizing data from the Clinical Practice Research Datalink (CPRD), which reflects the UK population. Participants included individuals aged 66 to 99 years, who had at least six years of data prior to a dementia diagnosis and a minimum of one year of exposure to an anticholinergic drug. Those excluded from the study included patients with diagnoses of HIV or AIDS, motor neuron disease, multiple sclerosis, Down’s syndrome, or a history of alcohol abuse before a dementia diagnosis.

Classification of Anticholinergic Effects

Due to the complexity of measuring the anticholinergic activity of drugs and their effects on the brain, researchers employed the Anticholinergic Cognitive Burden (ACB) scale for classification. ACB scores range from 1 to 3, indicating varying levels of anticholinergic activity, with higher scores suggesting a greater likelihood of clinically significant effects.

Key Findings: Association with Dementia

The analysis revealed a significant correlation between dementia and the prescription of any drug with an ACB score of 1, 2, or 3. There was also a dose-response relationship noted for anticholinergic drugs with ACB scores of 2 or 3.

Significant Links to Antidepressants

When categorized by drug class, researchers found a notable association between the incidence of dementia and the use of antidepressants, antiparkinsonian, or urological medications with an ACB score of 3. Antidepressant drugs with an ACB score of 1 also showed an increased incidence of dementia, although other drugs with the same score did not present similar findings. Additionally, patients prescribed an anticholinergic drug with an ACB score of 3 between fifteen and twenty years prior to a dementia diagnosis exhibited a significantly higher incidence of dementia.

Challenges in Diagnosing Dementia

The study’s results align with previous research examining the long-term cognitive effects of anticholinergic drugs. Its robust population size and extended patient history provided a clearer estimation of the effects of various anticholinergic drug classes on dementia incidence, extending up to 20 years before diagnosis. However, challenges such as under-diagnosis of dementia and misclassification of controls may have influenced the observed effects. Additionally, potential surveillance bias could arise as patients taking anticholinergic drugs may interact more frequently with healthcare services, making them more likely to receive a dementia diagnosis. The study also did not account for adherence to prescribed anticholinergic medications or the use of over-the-counter drugs that may have anticholinergic properties.

Clinical Implications

Despite the moderate associations found, the high prevalence of dementia in the population underscores the importance of considering this risk factor. Research on both humans and animal models supports the detrimental impact of anticholinergic drugs on cognitive function and overall brain health. Further investigation into specific drug classes with anticholinergic activity is necessary to fully understand the potential harms associated with their use.

Clinicians should remain vigilant regarding the short-term and long-term risks linked to anticholinergic drug use, particularly in relevant drug classes, when evaluating the risks and benefits for their patients.

Reference

Richardson, K., Fox, C., Maidment, I., Steel, N., Loke, Y. K., Arthur, A., . . . Savva, G. M. (2018). Anticholinergic drugs and risk of dementia: Case-control study. BMJ. doi:10.1136/bmj.k1315